Pfizer has made the decision to discontinue the clinical development program for danuglipron, an oral GLP-1 receptor agonist, being investigated for chronic weight management.

This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Leerink Partnrs analysts have boosted Pfizer’s Q2 2025 earnings forecast from $0.52 to $0.57 per share, showing newfound ...

Scientists have found that receiving a COVID-19 booster shot in the same arm as the initial dose triggers a faster and more effective immune response, thanks to primed macrophages in nearby lymph ...

A decision is expected in the fourth quarter of 2025.

As the state faces a multimillion dollar measles outbreak in West Texas, the House Public Health Committee passes HB 1586 ...

Financial Guidance Based on its current operating plan, Arvinas believes its cash, cash equivalents, and marketable securities as of March 31, 2025, is sufficient to fund planned operating expenses ...

Same-arm booster shots trigger a stronger early immune response than shots given in the opposite arm, leading to higher ...

Viking Therapeutics (VKTX) stock rises as Pfizer (PFE) plans to bolster its pipeline with cardiometabolic and other obesity drugs, through acquisitions. Read more here.

Pfizer (PFE) stock slips after the company's lower than expected Q1 2025 revenue and the firm seeks acquisitions to boost its ...

Sydney scientists have revealed why receiving a booster vaccine in the same arm as your first dose can generate a more ...